A Study of Neoadjuvant Chemotherapy Plus Nivolumab Versus Neoadjuvant Chemotherapy Plus Placebo, Followed by Surgical Removal and Adjuvant Treatment With Nivolumab or Placebo for Participants With Surgically Removable Early Stage Non-small Cell Lung Cancer
A phase 3 trial of Nivolumab, Carboplatin, Cisplatin, Pemetrexed and Docetaxel in non-small-cell lung cancer, run by Bristol-Myers Squibb, active and no longer recruiting.
Overview
A Study of Neoadjuvant Chemotherapy Plus Nivolumab Versus Neoadjuvant Chemotherapy Plus Placebo, Followed by Surgical Removal and Adjuvant Treatment With Nivolumab or Placebo for Participants With Surgically Removable Early Stage Non-small Cell Lung Cancer is a phase 3 interventional study registered as NCT04025879 by Bristol-Myers Squibb, with 461 participants enrolled, started 2019-11-05 and due to reach its primary completion in 2023-07-26. Interventions recorded: Nivolumab, Carboplatin, Cisplatin, Paclitaxel, Pemetrexed and Placebo. Results have been posted on the registry.
Similar pages
not linked directly; found by shared links- TrialCombination Therapies With Adagrasib in Patients With Advanced NSCLC With KRAS G12C Mutation
Shares Pemetrexed, Bristol Myers Squibb, Cisplatin, Carboplatin and the tag pipeline.
- TrialA Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
Shares Pemetrexed, Bristol Myers Squibb, Cisplatin, Carboplatin and the tag pipeline.
- TrialA Study of LP-300 With Carboplatin and Pemetrexed in Never Smokers With Advanced Lung Adenocarcinoma
Shares Pemetrexed, Carboplatin, Non-small-cell lung cancer and the tag pipeline.
- TrialASKC202 Combined With Limertinib Versus Platinum-based Chemotherapy in Treatment of Locally Advanced or Metastatic NSCLC With MET Amplification/Overexpression After Failure of EGFR-TKI Therapy
Shares Pemetrexed, Cisplatin, Carboplatin, Non-small-cell lung cancer and the tag pipeline.
- TrialSavolitinib Plus Osimertinib Versus Platinum-based Doublet Chemotherapy in Participants With Non-Small Cell Lung Cancer Who Have Progressed on Osimertinib Treatment
Shares Pemetrexed, Cisplatin, Carboplatin, Non-small-cell lung cancer and the tag pipeline.
- TrialA Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
Shares Pemetrexed, Cisplatin, Carboplatin, Non-small-cell lung cancer and the tag pipeline.
- TrialPhase III, Open-label, First-line Study of Dato-DXd in Combination With Durvalumab and Carboplatin for Advanced NSCLC Without Actionable Genomic Alterations
Shares Pemetrexed, Cisplatin, Carboplatin, Non-small-cell lung cancer and the tag pipeline.
- TrialStudy of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell Lung Cancer (NSCLC) (MK-7339-012/KEYLYNK-012)
Shares Pemetrexed, Cisplatin, Carboplatin, Non-small-cell lung cancer and the tag pipeline.